Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Do RA Patients in Clinical Trials for Biologics Represent the Average?

Arthritis Care & Research  |  October 4, 2016

Over the past 20 years, many randomized controlled trials have shown that biologic agents may result in slowed disease progression and improved physical function in patients with rheumatoid arthritis (RA). In clinical rheumatology practice, it’s estimated that 40–70% of patients have been exposed to a biologic.

“However, randomized controlled trials for biologic agents in RA have rigorous and non-standardized entry criteria, which may affect the external validity of generated findings and, thus, limit the generalizability to routine clinical practice.” write Priyanka Vashisht, MD, and colleagues from the VA Nebraska-Western Iowa Health Care System and Nebraska Arthritis Outcomes Research Center, University of Nebraska Medical Center in Omaha. “Therefore, it is critical to evaluate how study populations are assembled for randomized controlled trials in order to determine whether routine clinical patients differ in a meaningful way from those who participate in trials.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The research, published in the October 2016 issue of Arthritis Care & Research, reviewed the eligibility criteria from 30 regulatory randomized controlled trials of 10 U.S. Food and Drug Administration-approved biologic agents. Additionally, data for each biologic agent were grouped into three categories: tumor necrosis factor (TNF) inhibitors, non-TNF inhibitors and an oral Janus kinase inhibitor.

The inclusion criteria were then applied to patients enrolled in two large, observational clinical cohorts for RA: the Veterans Affairs Rheumatoid Arthritis registry (VARA; n=1,523) and the Rheumatology and Arthritis Investigational Network Database (RAIN-DB; n=1,548). Based on data from their baseline entry into the registries, patients were assessed across three domains of eligibility: RA disease activity, demographics and medication exposure.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
“We demonstrated that the vast majority of RA patients from our clinical cohorts (96.3% in VARA and 92.4% in RAIN-DB) did not satisfy criteria for participation in biologic agent randomized controlled trials,” write the authors in their discussion.

Only 3.7% of patients in VARA and 7.1% in RAIN-DB were eligible for inclusion based on disease activity alone.

For both cohorts, only 28-joint counts (tender and swollen) were available to calculate the Disease Activity Score (DAS28), along with the erythrocyte sedimentation rate and patient global well-being score components. In contrast, a majority of the study’s randomized controlled trials defined minimum thresholds of disease activity with joint counts of 68 possible tender and 66 possible swollen joints. As a result, “the domain most often attributable to patient exclusions in both cohorts was disease activity, specifically the minimum number of swollen and/or tender joints required,” write the authors. “The mean (range) DAS28 score was 6.59 (6.1–7.1) across the 19 randomized controlled trials groups at enrollment, in comparison to 3.8761.56 in VARA and 3.6561.33 in RAIN-DB.”

For demographics, the most common reason for trial exclusion was patients exceeding the disease duration maximum. On average, this aspect affected 10% of VARA patients and 2.5% of RAIN-DB patients across 20 of the trials. Additionally, a mean of 72% of VARA patients and 29% of RAIN-DB patients were excluded due to previous medication use. The authors write, “Prior methotrexate use, which excluded, on average, 16% in VARA and 6.8% in RAIN-DB, and the use of other disease-modifying anti-rheumatic drugs, which excluded, on average, 62% in VARA and 27% in RAIN-DB, were most striking.”

The authors note the importance of the aggressive treatment of RA, and in clinical practice, patients with fewer disease-affected joints are offered biologic agents as first-line therapy and/or when traditional disease-modifying anti-rheumatic drugs are not effective.

“These findings underscore the need for caution in extrapolating trial results to day-to-day management of RA patients,” write the authors. “Patients recruited into these studies commonly have much higher levels of disease activity than seen in clinical practice, and comparator arms may include placebo. … However, when eligibility criteria are overly restrictive, [the criteria] can compromise external validity and sacrifice the generalizability of the results to the patient populations in whom the answer to the question is desired.”

The authors note the value of observational data for putting the results of randomized clinical trials in perspective. “There is a need for more real world/observational studies to guide prescribing protocols and provide comparative effectiveness of the many medications in treating patients with RA in clinical practice,” they conclude.

Read the full article.

Vashisht P, Sayles H, Cannella AC, et al. Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res (Hoboken). 68(10):1478–1488. doi: 10.1002/acr.22860.

Page: 1 2 | Multi-Page
Share: 

Filed under:Biologics/DMARDs Tagged with:BiologicsBiologics & Biosimilarsclinical trialsnon-TNF biologicsrandomized controlled trialTNF inhibitors

Related Articles

    University of Nebraska Division of Rheumatology and Immunology Makes Education, Clinical Research Top Priorities

    August 13, 2017

    2016 ACR President Joan Van Feldt, MD, MSEd (L), and 2017 ACR President Sharad Lakhanpal, MBBS, MD (R), present Dr. O’Dell with the 2016 ACR Distinguished Clinical Investigator Award. When it was created in 1982, the Division of Rheumatology and Immunology at the University of Nebraska Medical Center comprised one-and-a-half rheumatologists: its founder, Lynell W. Klassen, MD,…

    Obesity Associated with Increased Inflammatory Markers in Rheumatoid Arthritis

    April 13, 2017

    NEW YORK (Reuters Health)—Obesity and higher fat mass are associated with increased levels of inflammatory markers in women with rheumatoid arthritis (RA), researchers report. “Physicians should recognize that C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are affected by obesity in patients with and without rheumatoid arthritis, especially in women,” Dr. Michael D. George from the University of…

    The Key to Early Rheumatoid Arthritis

    September 1, 2010

    The conundrum of classification versus diagnosis

    Obesity’s Effects on Inflammatory Markers in Patients with RA

    November 29, 2017

    New research has examined the effect of obesity on inflammatory markers, specifically C-reactive protein (CRP) level and erythrocyte sedimentation rate, in patients with rheumatoid arthritis (RA). Researchers found higher BMIs were associated with higher CRP levels in women both with and without RA, suggesting the phenomenon is related to adiposity and not an indication of disease activity. For men with RA, low BMI was associated with higher CRP levels, which proved to be RA-specific but not a direct causal effect of adiposity…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences